Cagrilintide
vs CagriSema.
Learn the difference between cagrilintide alone and CagriSema, including ingredients, REDEFINE 1 results, Phase 3 programs, and FDA status.
What is the difference?
Cagrilintide and CagriSema are related but not the same investigational treatment. Cagrilintide is a long-acting amylin analogue studied on its own. CagriSema is a fixed-dose combination of cagrilintide and semaglutide, a GLP-1 receptor agonist. REDEFINE 1 included separate randomized arms for cagrilintide alone and the combination. Novo Nordisk has submitted CagriSema to the FDA, while standalone cagrilintide continues in the RENEW Phase 3 program. Neither is currently FDA approved.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Cagrilintide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 52 matched NCT records
- Sponsor
- Novo Nordisk
CagriSema
Submitted to FDA - not yet approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 30 matched NCT records
- Sponsor
- Novo Nordisk
Cagrilintide vs CagriSema: how direct is the evidence?
Cagrilintide and CagriSema appeared in separate randomized arms of REDEFINE 1. The common protocol aligns important design fields, but the cited record does not necessarily establish that this exact pair was a prespecified and statistically powered superiority comparison.
Cagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
Same trial, but the exact contrast may be descriptive.
Use the shared protocol as stronger descriptive context while checking whether the exact pairwise contrast was prespecified and powered.
REDEFINE 1CagriSema
Amylin analogue + GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 / US regulatory review
- Status
- Submitted to FDA - not yet approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 10
- Results posted
- 2
- Recruiting site observations
- 170
matched NCT records
- Recruiting
- 5
- Results posted
- 0
- Recruiting site observations
- 155
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Use the shared protocol as stronger descriptive context while checking whether the exact pairwise contrast was prespecified and powered.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Cagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT03856047 · NCT05567796 · NCT07220642 · NCT07220759
CagriSema
Amylin analogue + GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 / US regulatory review
- Status
- Submitted to FDA - not yet approved
- Featured trial anchors
- NCT05567796 · NCT05669755 · NCT07011667
Compare the field, then read the limit.
This is an identity comparison before it is an efficacy comparison. Search results and seller catalogs sometimes use cagrilintide and CagriSema as if they were synonyms, but one is a single investigational molecule and the other contains two active components. Their trial results, regulatory records, and eventual labels cannot be transferred between names.
| Field | Cagrilintide | CagriSema | How to interpret it |
|---|---|---|---|
| Active components | Cagrilintide alone | Cagrilintide plus semaglutide | The addition of semaglutide makes CagriSema a different intervention, not a brand name for cagrilintide. |
| REDEFINE 1 anchor | 11.8% at 68 weeks under the trial-product estimand | 22.7% at 68 weeks under the trial-product estimand | These figures came from separate randomized arms in the same trial and must stay attached to the correct intervention. |
| Development path | Standalone RENEW Phase 3 program | REDEFINE Phase 3 program and FDA application | The two programs have distinct trial records and regulatory paths. |
| Current status | Investigational and not FDA approved | Submitted to the FDA and not yet approved | Neither status creates a legitimate retail product or approved dosing instruction. |
Why the headline numbers do not name a winner.
REDEFINE 1 is unusually useful because it randomized participants to CagriSema, cagrilintide, semaglutide, or placebo in one 68-week trial. The reported trial-product estimates were 11.8% for cagrilintide and 22.7% for CagriSema, each compared within the study design. Those group results still do not predict an individual's response, and the combination result must never be attached to cagrilintide monotherapy.
Keep the comparison honest.
- 01
Check whether a result belongs to cagrilintide monotherapy or to the cagrilintide plus semaglutide combination.
- 02
Use CagriSema for the fixed-dose combination and cagrilintide for the standalone amylin analogue program.
- 03
Do not transfer CagriSema's FDA application, trial percentage, or eventual label to cagrilintide alone.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →